Overview
Balance Sheet
Cash Flow
Growth Analysis
2024
2023
2023
2022
2021
Profitability Metrics
Gross Margin
65.34%
Operating Margin
15.89%
Net Margin
11.36%
Efficiency Metrics
Revenue per Expense Ratio
1.19
R&D as % of Revenue
8.45%
Earnings Quality
EBITDA Margin
25.35%
Income Tax Rate
23.42%
EPS
2.7700000000
Balance Sheet Analysis
Current Ratio
2.03
Cash Ratio
0.74
Working Capital
$11.15B
Debt to Equity
0.52
Debt to Assets
28.95%
Equity Ratio
55.81%
Cash Flow Analysis
Operating Cash Flow Ratio
20.97%
Free Cash Flow Ratio
16.07%
CapEx to Revenue
4.90%
Dividends Paid
$3.67B
Stock Buybacks
$2.14B
Total Shareholder Returns
$5.80B
Cash Position Change
-16.79%
Key Takeaways (2024 FY)
Increased dividend payments by 1.54%
Increased R&D investment by 1.45%
Detailed Growth Metrics
Core Performance
Revenue
3.64%
Net Income
-2.18%
EPS
-2.12%
Operating Income
-6.22%
Operational Efficiency
R&D Expenses
1.45%
SG&A Expenses
3.08%
Operating Cash Flow
12.39%
Free Cash Flow
13.54%
Balance Sheet Health
Assets
-1.06%
Debt
6.91%
Book Value per Share
-2.26%
Inventory
-1.44%
Shareholder Returns
Dividends per Share
1.54%
Shares Outstanding
-0.16%
Long Term Trends
3Y Revenue/Share
8.85%
5Y Revenue/Share
7.41%
3Y Dividend/Share
19.02%
5Y Dividend/Share
38.05%